Antifungal Resistance: Current Trends and Future Strategies

Dear Colleagues,

For decades, fungal infections have been a difficult health condition to treat. This can be attributed to the narrow spectrum and high toxicity of clinically used antifungals, the long duration of treatment, and the high emergence of resistance towards available agents. The severity of fungal infections was brought to light during the unfortunate COVID-19 pandemic, in the form of life-threatening secondary infections in intensive care units. Candida, Cryptococcus, and Aspergillus are the most common causative organisms of life-threatening human fungal infections. Candida auris is a multidrug resistant fungus. Lomentospora prolificans has intrinsic resistance to all clinically used antifungals. Aspergillus fumigatus is becoming more resistant to treatment, making it more difficult to treat aspergillosis, with the mortality rate reaching 100% in some cases. Early diagnosis and treatment of fungal meningitis and chronic pulmonary aspergillosis can save millions of lives worldwide. Fungal infections have become a silent crisis, and immediate efforts are needed before it is too late. In this Special Issue, we will highlight current cutting-edge developments in the antifungal pipeline.

For this Special Issue, we invite you to submit original or review articles on new antifungal molecules, formulations, resistances, or studies.

Dr. Matthew Donadu
Dr. Basem Battah
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.